Claims
- 1. A self-nanoemulsified drug delivery system, comprising
a) 19-26 wt. % of a pharmacologically effective drug; b) 23-31 wt. % polyoxyl 35 castor oil; c) 23-31 wt. % of a medium chain mono- and diglyderide; and d) 19-26 wt. % of an essential oil.
- 2. The self-nanoemulsified drug delivery system of claim 1, wherein said pharmacologically effective drug is selected from the group comprising ubiquinone, cyclosporine, and Vitamin E.
- 3. The self-nanoemulsified drug delivery system of claim 2, wherein said pharmacologically effective drug is ubiquinone.
- 4. The self-nanoemulsified drug delivery system of claim 3, wherein said essential oil is lemon oil.
- 5. The self-nanoemulsified drug delivery system of claim 4, comprising
a) about 23 wt. % ubiquinone; b) about 27 wt. % polyoxyl 35 castor oil; c) about 27 wt. % a medium chain mono- and diglyderide; and d) about 23 wt. % lemon oil.
- 6. A capsule formulation, comprising the self-nanoemulsified drug delivery system of claim 5.
- 7. The self-nanoemulsified drug delivery system of claim 1, wherein said essential oil is selected from the group comprising menthol, spearmint oil, peppermint oil, lemon oil, anise oils, and mixtures thereof.
- 8. The self-nanoemulsified drug delivery system of claim 7, wherein said essential oil is lemon oil.
- 9. The self-nanoemulsified drug delivery system of claim 1, wherein said polyoxyl 35 castor oil and said medium chain mono- and diglyceride are present in a ratio of 0.5 to 1.5.
- 10. A capsule formulation, comprising the self-nanoemulsified drug delivery system of claim 1.
- 11. A solid dosage form, comprising
a) 3-35 wt. % of a copolymer of vinylpyrrolidone and vinyl acetate; b) 11-47 wt. % microcrystalline cellulose; c) 35-82 wt. % maltodextrin; and d) an effective amount of said self-nanoemulsified drug delivery system of claim 1 for administering said pharmacologically effective drug to a patient.
- 12. The solid dosage form of claim 11, wherein said pharmacologically effective drug is selected from the group comprising ubiquinone, cyclosporine, and Vitamin E.
- 13. The solid dosage form of claim 12, wherein said pharmacologically effective drug is ubiquinone.
- 14. The solid dosage form of claim 11, wherein said essential oil is selected from the group comprising menthol, spearmint oil, peppermint oil, lemon oil, anise oils, and mixtures thereof.
- 15. The solid dosage form of claim 14, wherein said essential oil is lemon oil.
- 16. The solid dosage form of claim 11, comprising
a) 7.8 wt. % of said copolymer of vinylpyrrolidone and vinyl acetate, b) 11.7 wt. % microcrystalline cellulose, c) 65.4 wt. % maltodextrin, and d) 15.1 wt. % of said self-nanoemulsified drug delivery system.
- 17. The solid dosage form of claim 11, wherein 46.1-91.1 wt. % of said pharmacologically effective drug is emulsified in a dissolution medium within 45 minutes.
- 18. The solid dosage form of claim 17, wherein said pharmacologically effective drug is ubiquinone.
- 19. The solid dosage form of claim 11, wherein said pharmacologically effective drug is ubiquinone and said essential oil is lemon oil.
- 20. The solid dosage form of claim 19, wherein said self-nanoemulsified drug delivery system comprises,
a) about 23 wt. % ubiquinone; b) about 27 wt. % polyoxyl 35 castor oil; c) about 27 wt. % medium chain mono- and diglyderide; and d) about 23 wt. % lemon oil.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit, under 35 U.S.C. 119(e), of U.S. Provisional Application No. 60/331,292 filed Nov. 14, 2001, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60331292 |
Nov 2001 |
US |